Influence of Psychotropic Pro Re Nata Drug Use on Outcomes in Hospitalized Patients with Schizophrenia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: In the treatment of patients with schizophrenia, pro re nata (PRN) drugs are commonly prescribed for medical indications such as agitation, acute psychiatric symptoms, insomnia, and anxiety. However, high-quality evidence supporting the use of PRN medications is lacking, and these drugs are administered on the basis of clinical experience and habits. Therefore, the actual use of psychotropic PRN drugs and its influence on the patients’ outcomes need to be investigated. Methods: This study included 205 patients who underwent inpatient treatment for schizophrenia. We investigated the prescription of psychotropic drugs before admission and at discharge, as well as the dosing frequency of PRN drugs during hospitalization. We also examined the influence of psychotropic PRN drug use on hospitalization days, antipsychotic polypharmacy, and readmission rates. Results: Patients who used psychotropic PRN drugs during hospitalization had significantly longer hospitalization days (p = 7.5 × 10−4 ) and significantly higher rates of antipsychotic polypharmacy (p = 2.4 × 10−4 ) at discharge than those who did not use psychotropic PRN drugs. Moreover, a higher number of psychotropic PRN drugs used per day was associated with higher readmission rates within 3 months of discharge (p = 4.4 × 10−3 ). Conclusion: Psychotropic PRN drug use is associated with prolonged hospitalization, antipsychotic polypharmacy, and increased readmission rates in inpatients with schizophrenia. Therefore, psychiatric symptoms should be stabilized with regularly prescribed medications without the extensive use of psychotropic PRN drugs. Moreover, a system for monitoring and reexamining PRN drug use needs to be established.
Abstract
Objective: In the treatment of patients with schizophrenia, pro re nata (PRN) drugs are commonly prescribed for medical indications such as agitation, acute psychiatric symptoms, insomnia, and anxiety. However, high-quality evidence supporting the use of PRN medications is lacking, and these drugs are administered on the basis of clinical experience and habits. Therefore, the actual use of psychotropic PRN drugs and its influence on the patients’ outcomes need to be investigated. Methods: This study included 205 patients who underwent inpatient treatment for schizophrenia. We investigated the prescription of psychotropic drugs before admission and at discharge, as well as the dosing frequency of PRN drugs during hospitalization. We also examined the influence of psychotropic PRN drug use on hospitalization days, antipsychotic polypharmacy, and readmission rates. Results: Patients who used psychotropic PRN drugs during hospitalization had significantly longer hospitalization days (p = 7.5 × 10−4 ) and significantly higher rates of antipsychotic polypharmacy (p = 2.4 × 10−4 ) at discharge than those who did not use psychotropic PRN drugs. Moreover, a higher number of psychotropic PRN drugs used per day was associated with higher readmission rates within 3 months of discharge (p = 4.4 × 10−3 ). Conclusion: Psychotropic PRN drug use is associated with prolonged hospitalization, antipsychotic polypharmacy, and increased readmission rates in inpatients with schizophrenia. Therefore, psychiatric symptoms should be stabilized with regularly prescribed medications without the extensive use of psychotropic PRN drugs. Moreover, a system for monitoring and reexamining PRN drug use needs to be established.
참고문헌 (38)
- Friedman R, "Using structured clinical feedback to encourage alternatives to use of"P. R. N. "medication in a state psychiatric hospital", J Psychiatr Pract, 18, pp.381~387 (2012)
- Morkunas B, "Experiences of mental health professionals and patients in the use of pro re nata medication in acute adult mental healthcare settings : a systematic review", JBI Database System Rev Implement Rep, 14, pp.209~250 (2016)
- Srivastava A, "Limited evidence for the effectiveness of p. r. n. medications among psychiatric inpatients", J Psychiatr Pract, 15, pp.193~201 (2009)
- Baker JA, "A best-evidence synthesis review of the administration of psychotropic pro re nata(PRN)medication in in-patient mental health settings", J Clin Nurs, 17, pp.1122~1131 (2008)
- Martin K, "Descriptive analysis of pro re nata medication use at a Canadian psychiatric hospital", Int J Ment Health Nurs, 26, pp.402~408 (2017)
- Fujita J, "Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia", Psychiatry Clin Neurosci, 67, pp.345~351 (2013)
- Baker JA, "Mental health professionals’ psychotropic pro re nata(p. r. n. )medication practices in acute inpatient mental health care : a qualitative study", Gen Hosp Psychiatry, 29, pp.163~168 (2007)
- Gallego JA, "Safety and tolerability of antipsychotic polypharmacy", Expert Opin Drug Saf, 11, pp.527~542 (2012)
- Jung-Jin Kim, "Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia", Clinical Psychopharmacology and Neuroscience, 19(4), pp.600~609 (2021), 대한정신약물학회[DOI]
- Hilton MF, "Pro re nata medication for psychiatric inpatients : time to act", Aust N Z J Psychiatry, 42, pp.555~564 (2008)
- Douglas-Hall P, "‘As required’ medication regimens for seriously mentally ill people in hospital", Cochrane Database Syst Rev, 2015, pp.CD003441~ (2015)
- Martin K, "Analysis of nonpharmacological interventions attempted prior to pro re nata medication use", Int J Ment Health Nurs, 27, pp.296~302 (2018)
- Abdallah MS, "PRN medications ordering practice at a large intensive care unit in Saudi Arabia", J Intensiv Crit Care, 2, pp.26~ (2016)
- Neumann RD, "Examining trends in the administration of"as needed"medications to inpatients with behavioral and psychological symptoms of dementia", Am J Alzheimers Dis Other Demen, 30, pp.247~256 (2015)
- Voderholzer U, "Are there gender differences in objective and subjective sleep measures? A study of insomniacs and healthy controls", Depress Anxiety, 17, pp.162~172 (2003)
- Ichihashi K, "The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder : a nationwide survey from the EGUIDE project", Asian J Psychiatr, 69, pp.103007~ (2022)
- Hasan A, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of schizophrenia-a short version for primary care", Int J Psychiatry Clin Pract, 21, pp.82~90 (2017)
- Galletly C, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders", Aust N Z J Psychiatry, 50, pp.410~472 (2016)
- Kuipers E, "Management of psychosis and schizophrenia in adults : summary of updated NICE guidance", BMJ, 348, pp.g1173~ (2014)
- Remington G, "Guidelines for the pharmacotherapy of schizophrenia in adults", Can J Psychiatry, 62, pp.604~616 (2017)
- Japanese Society of Neuropsychopharmacology, "Japanese Society of Neuropsychopharmacology : "Guideline for Pharmacological Therapy of Schizophrenia"", Neuropsychopharmacol Rep, 41, pp.266~324 (2021)
- American Psychiatric Association, "Practice guideline for the treatment of patients with schizophrenia" (2019), American Psychiatric Association
- Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia : updated recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 34, pp.3~78 (2020)
- "Violence and aggression: short-term management in mental health, health and community settings" (2015)[URL]
- Ichihashi K, "Prescription patterns in patients with schizophrenia in Japan : first-quality indicator data from the survey of"Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment(EGUIDE)"project", Neuropsychopharmacol Rep, 40, pp.281~286 (2020)
- Hudson CG, "Five-year rehospitalization experience of a statewide cohort of persons with schizophrenia", Soc Psychiatry Psychiatr Epidemiol, 54, pp.861~870 (2019)
- Schennach R, "What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial", Eur Arch Psychiatry Clin Neurosci, 270, pp.661~671 (2020)
- Sampson S, "Intermittent drug techniques for schizophrenia", Cochrane Database Syst Rev, (7), pp.CD006196~ (2013)
- Takeuchi H, "Antipsychotic treatment for schizophrenia in the maintenance phase : a systematic review of the guidelines and algorithms", Schizophr Res, 134, pp.219~225 (2012)
- Takaesu Y, "Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the ’Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment(EGUIDE)’ project : a nationwide dissemination, education, and evaluation study", Psychiatry Clin Neurosci, 73, pp.642~648 (2019)
- Donat DC, "Encouraging alternatives to seclusion, restraint, and reliance on PRN drugs in a public psychiatric hospital", Psychiatr Serv, 56, pp.1105~1108 (2005)
- Mistler LA, "Mobile mindfulness intervention on an acute psychiatric unit : feasibility and acceptability study", JMIR Ment Health, 4, pp.e34~ (2017)
- Richmond JS, "Verbal de-escalation of the agitated patient : consensus statement of the American Association for Emergency Psychiatry Project BETA de-escalation workgroup", West J Emerg Med, 13, pp.17~25 (2012)
- Curtis J, "Exploration of therapeutic interventions that accompany the administration of p. r. n. (‘as required’)psychotropic medication within acute mental health settings : a retrospective study", Int J Ment Health Nurs, 16, pp.318~326 (2007)
- Smith GM, "Psychiatric use of unscheduled medications in the Pennsylvania state hospital system : effects of discontinuing the use of P. R. N. orders", Community Ment Health J, 44, pp.261~270 (2008)
- Smith GM, "Correlation between reduction of seclusion and restraint and assaults by patients in Pennsylvania’s state hospitals", Psychiatr Serv, 66, pp.303~309 (2015)
- Hipp K, "Patient participation in pro re nata medication in psychiatric inpatient settings : an integrative review", Int J Ment Health Nurs, 27, pp.536~554 (2018)
- Barr L, "Nurses’ attitudes towards the use of PRN psychotropic medications in acute and forensic mental health settings", Int J Ment Health Nurs, 27, pp.168~177 (2018)